Antibodies for p47phox and gapdh

GXSTC consists of five traditional Chinese drugs: 57.1% Fructus Choerospondiatis (Polyphagidae), 28.6% Salvia miltiorrhiza (Labiatae), 7.1% Syzygium aromaticum (Labiatae), 3.6% borneol (Leguminosae) and 3.6% tabasheer. GXSTC (batch no. 20120125) was provided by Buchang Pharmaceuticals (Xi’an, China). DMEM and fetal bovine serum were obtained from Gibco-BRL (Grand Island, NY, USA). The recombinant human TNF-α was obtained from Promega Corp. (Madison, WI, USA). The anti-endothelial NOS (eNOS) and anti-AKT monoclonal antibodies were purchased from Cell Signaling Technology, Inc. (Boston, MA, USA). Antibodies for p47phox and GAPDH were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and those for gp91phox and NAPDH oxidase 4 (Nox4) were purchased from Epitomics (Burlingame, CA, USA). Enhanced chemiluminescence reagent was obtained from Pierce Biotechnology, Inc. (Rockford, IL, USA). All primers used were provided by Takara Bio, Inc. (Shiga, Japan), and the NO, NOS, superoxide dismutase (SOD), malondialdehyde (MDA) and lactate dehydrogenase (LDH) assay kits were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

Human CGRP, Human CGRP_8–37, Ang II, N‐acetyl‐L cysteine (NAC), apocynin, PP2, H‐89 and dibutyl‐cAMP were purchased from Sigma. Niclosamide was purchased from Selleck Chemicals; anti‐phospho‐Src (Tyr416), anti‐phospho‐STAT3 (Tyr705), Src and STAT3 antibodies, from Cell Signaling Technology Inc; antibodies for p47phox and GAPDH, and all secondary antibodies, from Santa Cruz Biotechnology; antibodies of RAMP1, CRLR and ATP1a1, from Santa Cruz Biotechnology; RCP antibodies, from NOVUS Institute of Biotechnology; Alzet mini‐osmotic pumps (Alzet model 1004), from DURECT Corp; and the Src (B0107) and STAT3 (F0806) ORF cDNA clones, from GeneCopoeia. Other chemicals and reagents were of analytical grade.